Amarin | AMRN - Cash And Equivalent

Stock Price
14.56
Daily Change
-0.22 -1.49%
Monthly
-1.09%
Yearly
37.62%
Q2 Forecast
14.12

Amarin reported $131.06M in Cash and Equivalent for its fiscal quarter ending in March of 2026.





Cash And Equivalent Change Date
AbbVie USD 9.39B 4.16B Mar/2026
Alnylam Pharmaceuticals USD 1.71B 53.53M Mar/2026
Amarin USD 131.06M 3.6M Mar/2026
AstraZeneca USD 7.56B 1.85B Mar/2026
BioCryst Pharmaceuticals USD 171.59M 164.32M Mar/2026
DBV Technologies USD 194.17M 124.33M Dec/2025
Esperion Therapeutics USD 156.16M 11.69M Mar/2026
GlaxoSmithKline GBP 3.44B 292M Mar/2026
Halozyme Therapeutics USD 309.75M 175.93M Mar/2026
Heron Therapeutics USD 26.12M 2.53M Mar/2026
Ionis Pharmaceuticals USD 1.92B 758M Mar/2026
Nektar Therapeutics USD 15.12M 25.92M Dec/2025
Neurocrine Biosciences USD 266.5M 446.5M Mar/2026
Novartis USD 6.88B 4.56B Mar/2026